Exphar
ActiveFrom the official registers: KBO 45 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
Exphar has been active since 1981 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €5.5m and a net result of €868,458. Equity has been growing by about 5.9% per year since 2018. Its solvency ranks better than 43% of 6,167 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Official details
KBO- Status
- Active since 27-08-1981 Normal situation
- Activity
- Wholesale of pharmaceutical and medical goods NACE 46460
- Establishment unit
- 2.226.977.171 1402 Nivelles, since 16-01-2014
- Financial year end
- 31 December
- Peppol
- Reachable
Board and ownership
- LHVK SPRLManaging director · permanent representative Laurent Haverbeke
- Jean-Olivier CollinetDirector · since 07-01-2025
- Koen SmessaertDirector · since 15-06-2026
- KoenSMESSAERTDirector
- Ricardo Alvès MartinsDirector
- Holdings
- Shares in 3 companies including EXPHARLAB LIMITED and H&H Pharma LTD
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
- Turnover
- €22.9m
- ▲ 2.1%
- Profit
- €868,458
- ▲ 119%
- Equity
- €5.5m
- ▲ 17.9%
- Total assets
- €14.1m
- ▼ 12.6%
- Staff
- 27 FTE
- ▲ 12.0%
Score breakdownlowers riskFounded in 1981Profit of €868,458 (financial year 2025)Liquidity: current ratio 1.68, cash €1.8mSize: turnover €22.9m, 27 FTE, total assets €14.1mShow the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, small). It does better than 46% of them on solvency, 64% on liquidity, 59% on profitability and 68% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 9 days before the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
Key points
Comparable companies
These companies have the same main activity as Exphar: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €8.6m and €16m, founded between 1978 and 1987.
| Company | Total assets | Turnover |
|---|---|---|
| Exphar Nivelles | €14.1m | €22.9m |
| CEVA SANTE ANIMALE Brussel | €13.6m | €30.8m |
| GOHY S.A. Dison | €16.0m | €31.5m |
| S.A Therabel-Pharma N.V. Vorst | €12.8m | €15.7m |
| LOUIS WIDMER Brussel | €10.4m | €23.5m |
| ELSCOLAB Beveren-Kruibeke-Zwijndrecht | €10.3m | €16.3m |
| BIO-RAD LABORATORIES Lokeren | €8.6m | €27.2m |
Documents
Annual accounts at the NBB
- Annual accounts 2025filed on 14-07-2026
- Annual accounts 2024filed on 04-08-2025
- Annual accounts 2023filed on 25-06-2024
- Annual accounts 2022filed on 18-07-2023
Acts in the Belgian Official Gazette
- Resignations & appointmentsact of 29-09-2026
- Resignations & appointmentsact of 01-08-2025
- Resignations & appointmentsact of 15-07-2024
- Resignations & appointmentsact of 08-08-2023
Articles and registers
- Coordinated articles of associationnotaries' database
- Entry in the KBO registerKBO Public Search
Key facts about Exphar
- What is the company number of Exphar?
- The company number of Exphar is 0421.802.718. The VAT number is the same number with BE in front: BE 0421.802.718.
- Where is Exphar based?
- The registered office is at Avenue Thomas Edison 105, 1402 Nivelles.Company details
- What does Exphar do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of Exphar?
- The legal form of Exphar is Public limited company (NV).
- When was Exphar founded?
- Exphar was founded on 27-08-1981.
- Is Exphar still active?
- Yes, Exphar is an active enterprise in the KBO register.
- How many employees does Exphar have?
- Exphar had an average of 27 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of Exphar?
- The turnover of Exphar was €22.9m in financial year 2025, according to the filed annual accounts.
- Is Exphar profitable?
- In financial year 2025, Exphar made a profit of €868,458.
- Where can I find the annual accounts of Exphar?
- Exphar filed 45 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
- When are the next annual accounts of Exphar due?
- Exphar must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.